Brief: Neurocrine Biosciences Provides Update On Phase 2 Data For Luvadaxistat In Adults With Cognitive Impairment Associated With Schizophrenia
12/09/2024 22:53
Sept 12 (Reuters) - Neurocrine Biosciences Inc NBIX.O :
* NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON ERUDITE™ PHASE 2
DATA
FOR LUVADAXISTAT IN ADULTS WITH COGNITIVE IMPAIRMENT ASSOCIATED
WITH SCHIZOPHRENIA
* NEUROCRINE BIOSCIENCES INC - LUVADAXISTAT DID NOT MEET
PRIMARY
ENDPOINT IN THIS STUDY
* NEUROCRINE BIOSCIENCES INC - PLAN TO HALT FURTHER
DEVELOPMENT OF
LUVADAXISTAT AT THIS TIME
* NEUROCRINE BIOSCIENCES- WILL FOCUS EFFORTS AND RESOURCES
ON
ADVANCEMENT INTO PHASE 3 CLINICAL DEVELOPMENT OF NBI-1117568 FOR
SCHIZOPHRENIA
Source text for Eikon: ID:nPn1tm5Bfa
Further company coverage: NBIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall